Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Dolly Saoirse O.; Wagner Andrew J.; Bendell Johanna C.; Kindler Hedy L.; Krug Lee M.; Seiwert Tanguy Y.; Zauderer Marjorie G.; Lolkema Martijn P.; Apt Doris; Yeh Ru-Fang; Fredrickson Jill O.; Spoerke Jill M.; Koeppen Hartmut; Ware Joseph A.; Lauchle Jennifer O.; Burris Howard A. III; de Bono Johann S.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

【24h】

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

机译：晚期实体瘤患者中的Apitolisib（GDC-0980），双重磷脂酰肌醇-3-激酶和哺乳动物靶点雷帕霉素激酶抑制剂的I期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: This first-in-human phase I trial assessed the safety, tolerability, and preliminary antitumor activity of apitolisib (GDC-0980), a dual inhibitor of class I PI3K, and mTOR kinases.

机译：目的：这项首次在人类中进行的I期临床试验评估了Apitolisib（GDC-0980），I类PI3K的双重抑制剂和mTOR激酶的安全性，耐受性和初步的抗肿瘤活性。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2016年第12期|共11页
作者
Dolly Saoirse O.; Wagner Andrew J.; Bendell Johanna C.; Kindler Hedy L.; Krug Lee M.; Seiwert Tanguy Y.; Zauderer Marjorie G.; Lolkema Martijn P.; Apt Doris; Yeh Ru-Fang; Fredrickson Jill O.; Spoerke Jill M.; Koeppen Hartmut; Ware Joseph A.; Lauchle Jennifer O.; Burris Howard A. III; de Bono Johann S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors [J] . Dolly Saoirse O., Wagner Andrew J., Bendell Johanna C., Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第12期

机译：晚期实体瘤患者中的Apitolisib（GDC-0980），双重磷脂酰肌醇-3-激酶和哺乳动物靶点雷帕霉素激酶抑制剂的I期研究
2. A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma [J] . Ding X., Li F., McKnight J., Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis . 2014,第Null期

机译：支持的液体萃取LC-MS / MS法测定人血浆中GDC-0980（Apitolisib），1A类磷酸肌醇3激酶和哺乳动物雷帕霉素靶标的双重小分子抑制剂
3. A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors [J] . Wainberg Z., Tabernero J., Maqueda M. A., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：I期研究对雷帕霉素（mTOR）抑制剂PF-05212384与伊立替康联用的双重静脉内（IV）磷脂酰肌醇3-激酶（PI3K）/哺乳动物靶点在患有结直肠癌（CRC）和其他晚期固体的患者（pts）中肿瘤
4. SHORT-TERM TUMOR RESPONSE TO TYROSINE KINASE INHIBITORS VERSUS LONG-TERM SURVIVAL IN MAST CELL TUMORS: FOLLOW-UP DATA FROM A PIVOTAL FIELD STUDY WITH MASITINIB [C] . Olivier Hermine Annual Conference of the Veterinary Cancer Society . 2009

机译：短期肿瘤对酪氨酸激酶抑制剂的反应与肥大细胞肿瘤的长期存活：来自Masitinib的关键田间研究的后续数据
5. Modulating the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway for therapeutic enhancement of photodynamic therapy. [D] . Fateye, Babasola. 2012

机译：调节磷脂酰肌醇3-激酶/雷帕霉素途径的哺乳动物靶标，以增强光动力疗法的治疗效果。
6. Phase I Study of Apitolisib (GDC-0980) Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor in Patients with Advanced Solid Tumors [O] . Saoirse O. Dolly, Andrew J. Wagner, Johanna C. Bendell, -1

机译：在晚期实体瘤患者中进行的Apitolisib（GDC-0980）双重磷脂酰肌醇-3-激酶和哺乳动物靶点雷帕霉素激酶抑制剂的I期研究
7. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors [O] . Dolly, S.O. (Saoirse O.), Wagner, Andrew, Bendell, J.C. (Johanna C.), 2016

机译：晚期实体瘤患者中的Apitolisib（GDC-0980），双重磷脂酰肌醇3-激酶和哺乳动物雷帕霉素激酶抑制剂靶点的I期研究

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

摘要

著录项

相似文献

相关主题

期刊订阅